Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab With or Without Carboplatin in Triple-Negative Metastatic Breast Cancer
NCT00232505Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Nov 2005
- Primary completion
- Jun 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of KL-140 in breast cancer (2 arms), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Overall Disease Response Rate at 5 years. Started Nov 2005; status: completed.
02
Drugs
KL-140
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00232505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00232505.